Cost of medical care for malignant brain tumors at hospitals in the Japan Clinical Oncology Group brain-tumor study group
Kazuya Motomura,Keita Sasaki,Narushi Sugii,Shigeru Yamaguchi,Hirotaka Inoue,Akito Oshima,Kazuhiro Tanaka,Yoshihiro Otani,Mitsuaki Shirahata,Ichiyo Shibahara,Motoo Nagane,Shunsuke Tsuzuki,Tomoo Matsutani,Yoshihiro Tsukamoto,Noriyuki Kijima,Kenichiro Asano,Makoto Ohno,Akihiro Inoue,Yohei Mineharu,Keisuke Miyake,Yuta Mitobe,Mitsuto Hanihara,Yu Kawanishi,Shoichi Deguchi,Masato Saito,Ryosuke Matsuda,Kenta Ujifuku,Hideyuki Arita,Yuichi Sato,Shinji Yamashita,Ushio Yonezawa,Junya Yamaguchi,Yasutomo Momii,Takahiro Ogawa,Atsushi Kambe,Shigeo Ohba,Junya Fukai,Norihiko Saito,Masashi Kinoshita,Koichiro Sumi,Ryohei Otani,Takeo Uzuka,Noriyoshi Takebe,Shinichiro Koizumi,Ryuta Saito,Yoshiki Arakawa,Yoshitaka Narita,Members of Japan Clinical Oncology Group Brain Tumor Study Group (JCOG-BTSG)
DOI: https://doi.org/10.1093/jjco/hyae116
2024-09-02
Abstract:Background: This study aimed to investigate what treatment are selected for malignant brain tumors, particularly glioblastoma (GBM) and primary central nervous system lymphoma (PCNSL), in real-world Japan and the costs involved. Methods: We conducted a questionnaire survey regarding treatment selections for newly diagnosed GBM and PCNSL treated between July 2021 and June 2022 among 47 institutions in the Japan Clinical Oncology Group-Brain Tumor Study Group. We calculated the total cost and cost per month of the initial therapy for newly diagnosed GBM or PCNSL. Results: The most used regimen (46.8%) for GBM in patients aged ≤74 years was 'Surgery + radiotherapy concomitant with temozolomide'. This regimen's total cost was 7.50 million JPY (Japanese yen). Adding carmustine wafer implantation (used in 15.0%), TTFields (used in 14.1%), and bevacizumab (BEV) (used in 14.5%) to the standard treatment of GBM increased the cost by 1.24 million JPY for initial treatment, and 1.44 and 0.22 million JPY per month, respectively. Regarding PCNSL, 'Surgery (biopsy) + rituximab, methotrexate, procarbazine, and vincristine (R-MPV) therapy' was the most used regimen (42.5%) for patients of all ages. This regimen incurred 1.07 million JPY per month. The three PCNSL regimens based on R-MPV therapy were in ultra-high-cost medical care (exceeding 1 million JPY per month). Conclusions: Treatment of malignant brain tumors is generally expensive, and cost-ineffective treatments such as BEV are frequently used. We believe that the results of this study can be used to design future economic health studies examining the cost-effectiveness of malignant brain tumors.